65,437 trials
Aphakia · Cataract
Primary: Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better — 21 Eyes
Stroke
Primary: Patient Quality of Life — 3.41; 3.91; 2.51; 2.67 score on a scale — p=0.029
Gun Violence Prevention
Primary: Change in Knowledge About Gun Violence — 2.49; 2.54; 2.94; 2.66 score on a scale
Pharmacology
Primary: Number of Participants With Treatment-emergent Adverse Events of HM15912 — 3; 1; 2; 4 Participants
Painful Osteoarthritis of the Knee
Primary: Change From Baseline in Weekly Average of Daily Numerical Rating Scale (NRS) Pain Score to Week 12 — -2.19; -3.00; -2.83; -2.81 Unit on a scale — p=0.360
Development Delay · Development, Child
Primary: Evaluation of the Child's Cognitive Functioning (i.e., Sensorimotor Development, Problem Solving Skills) — 83.50; 81.94 score on a scale — p=0.30
Type 2 Diabetes
Primary: Number of Participants With Adverse Events [Safety and Tolerability of GLY-200] — 9; 8; 12; 7 Participants
Carpal Tunnel Syndrome
Primary: Post-operative Pain — 1.16; 0.92 score on a scale — p=<0.05
Opioid-use Disorder · Opiate Dependence
Primary: Drug Cue+ Stressor Induced Craving — 1.52; 1; 1.72; 1.96 units on a scale
Type II Diabetes · Primary Health Care · Behavioral Health
Primary: Acceptability of Intervention — 0.60 units on a scale
Acute Wounds
Primary: Percentage of Wound Dressing Changes Associated With a Pain <30 mm on Visual Analog Scale (VAS) — 97.4; 97.5 percentage of dressing changes
Cervical Cancer
Primary: Pre-crossover Period: Independent Review Committee (IRC)-Assessed Objective Response Rate (ORR) — 15.6; 19.0 percentage of participants
Dentin Hypersensitivity
Primary: Change in Pain From Baseline Immediately After Application of Test Product. — 8.9; 8.6 units on a scale
type1diabetes
Primary: Percentage of Enrolled of Eligible Participants Screened — 42 Participants
Prader-Willi Syndrome · Hyperphagia
Primary: Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT) — -6.08; -6.64 score on a scale